SEARCH

SEARCH BY CITATION

Summary

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

The armamentarium of medications for the treatment of inflammatory bowel disease is growing and becoming more complicated to use. Immunomodulators are a class of medications that have found a niche for the treatment of Crohn's disease and ulcerative colitis. Because of the mounting supporting evidence for efficacy, the most commonly-used immunomodulators are azathioprine, mercaptopurine, methotrexate and ciclosporin. These medications are being used more often due to their steroid-sparing and potentially surgery-sparing effects. Immunomodulators are also known for a significant side-effect profile and require careful monitoring. This review provides the latest information for clinicians on efficacy, side-effects, dosing and monitoring of these medications for treatment of inflammatory bowel disease.


Introduction

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Treatment of inflammatory bowel diseases (IBD) commonly requires utilization of immunodulatory medications. This class of medications includes azathioprine (AZA), mercaptopurine (MP), ciclosporin, methotrexate, and on occasion mycophenolate mofetil and tacrolimus. The most commonly used immunomodulators for treatment of IBD are AZA, MP, ciclosporin and methotrexate. These medications have shown to be effective and great care must be taken in monitoring patients receiving these medications to maximize clinical benefit and reduce the risk of side-effects and toxicity. This review will provide information on clinical pharmacology, clinical indications for use, methods of dose adjusting, monitoring of metabolites for efficacy and for potential side-effects, and the adverse event profile for each medication. This review will hopefully provide guidance on utilizing immunomodulators for Crohn's disease (CD) and ulcerative colitis (UC) based on the published literature.

Methods

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

A Medline search was conducted from 1966 to 2004, for randomized-controlled trials of AZA, MP, ciclosporin and methotrexate for the treatment of IBD. A Medline search was also completed for studies assessing monitoring efficacy and toxicity of these medications in the setting of IBD. Additional references were obtained and reviewed from a search in BIOSIS Previews, a database, which includes published abstracts, and if pertinent literature was known to the authors or identified during searches. All searches were limited to the English language.

Clinical pharmacology

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Mercaptopurine and the nitroimidazole derivative of MP, AZA, are thiopurine analogues. AZA is non-enzymatically metabolized to MP. MP is metabolized to 6-thioinosine 5′-monophosphate (TIMP) by the enzyme hypoxanthine phosphoribyl transferase (HPRT). TIMP is eventually metabolized to 6-tioguanine (thioguanine) nucleotides (6-TGN) (see Figure 1). 6-TGN has been shown to bind to Rac1 instead of guanine triphosphate and with co-stimulation with CD28 leads to inhibition of Rac1 and apoptosis of T-lymphocytes.1 MP is also metabolized to 6-methylmercaptopurine (6-MMP) by the enzyme thiopurine methyltransferase (TPMT) and 6-thiouric acid by the enzyme xanthine oxidase (XO). Both 6-thiouric acid and 6-MMP are inactive metabolites of MP. The three enzymes metabolizing MP are in constant competition for substrate and the concentration of the metabolites of MP are based on the concentrations of these enzymes. About 84% of MP is quickly metabolized by XO found in high concentrations in enterocytes and hepatocytes, leaving only 16% left to be catabolized by TPMT and HPRT.2

image

Figure 1. Metabolism of azathioprine (AZA) and mercaptopurine (MP). 6-TU, 6-thiouric acid; 6-MMP, 6-methyl mercaptopurine; 6-MMPR, 6-methyl mercaptopurine ribonucleotides; 6-TIMP, 6-thioinosine 5′-monophosphate; 6-TXMP, 6-thioxanthosine 5′-monophosphate; 6-TGN, 6-tioguanine nucleotides; XO, xanthine oxidase; TPMT, thiopurine methyltransferase; HPRT, hypoxanthine phosphoribosyltransferase; IMPDH, inosine monophosphate dehydrogenase; GMPS, guanosine monophosphate synthetase.

Download figure to PowerPoint

Genetic variation of metabolism.  Mutations of the gene encoding TPMT leading to varying functional activity of the enzyme have been identified in the population. There are at least 12 mutant alleles responsible for TPMT deficiency and several silent and intronic mutations have been described for the TPMT gene located on chromosome 6.3, 4 The most common of these variants is the normal TPMT*1 or wild-type allele. TPMT*3A is the most common mutant allele and seen predominantly in Caucasians. TPMT*3C is the most prevalent variant in African-American and Asian populations.5–10 Homozygous mutations of the TPMT gene produce enzyme with minimal activity and accounts for 0.3% of the general population.11, 12 Heterozygous mutations yield enzyme with moderate activity and accounts for 11% of the general population.11 A recent study in patients with CD has shown the frequency of homozygous and heterozygous TPMT mutations parallels the frequency in the general population.12 TPMT level is measured from lysed erythrocytes and the TPMT level corresponds to that in liver, kidney and lymphocytes.13 TPMT activity appears to be inversely correlated with drug response. TPMT genotyping is also available but limited to the allelic variants that are known. More detail is given utilizing TPMT activity for tailoring treatment with AZA or MP in the following sections.

Indication and dosing

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

There have been several clinical trials supporting the use of AZA and/or MP for the treatment of the following indications: active CD, maintenance of remission of CD, fistulizing CD, prevention of post-operative recurrence of CD, maintenance of remission of UC, and as a steroid-sparing agent. In a meta-analysis of randomized-controlled trials from 1966 to 1994 of AZA and MP in active and quiescent CD the odds ratio (OR) for a clinical response to therapy of active CD was 3.09 (95% CI: 2.45–3.91), 1.45 (95% CI: 1.12–1.87) without the one clinical trial with MP.14 For quiescent CD the OR for maintaining remission if on AZA was 2.27 (95% CI: 1.76–2.93). Both longer duration and higher dose of AZA/MP was associated with improved response and a steroid-sparing effect was seen in subjects with active and quiescent disease. Several studies have also shown a steroid dose reduction with the addition of MP and AZA to therapy.15–22 MP and AZA have also been found to be useful in the treatment of fistulizing CD with several studies showing a higher response of complete closure or decreased drainage of fistulas.17, 21, 23 There is also emerging data supporting MP and AZA use for CD post-operative prevention of recurrence of in those with previous history of surgeries and perforating disease.24–28 In UC, AZA and MP appear to be most useful in maintaining remission and as a steroid-sparing agent.29

The mercaptopurine and AZA have a significantly delayed onset of action with several studies showing clinical benefit after 2–3 months of treatment.17, 21 The best approach if rapid clinical response is needed is to start another form of therapy such as corticosteroids or infliximab until the period of clinical onset is achieved. It is not yet clear what the ideal length of therapy for maintenance of remission should be. A study by Bouhnik et al. showed a low relapse rate of <20% in patients in remission who used AZA for 4 years or more, 2 years after completing therapy. The relapse rate was similar to those that continued AZA therapy.30 In a recent study published in abstract form by Lemann et al., 19% relapsed at 18 months and 60% relapsed at 54 month after AZA was stopped for maintenance of remission of CD.31

For CD and UC the most effective doses appear to be 2.5 mg/kg of AZA and 1.5 mg/kg of MP, although there has not yet been a head-to-head comparison at various dose levels, or a comparative trial evaluating efficacy of MP vs. AZA in patients with IBD. There are two methods for starting therapy, dose escalating to the weight-based dose vs. starting immediately at the weight-calculated dose. Dose escalating came into practice due to the fear of dose-related toxicities such as leucopoenia, thrombocytopenia and hepatitis. Whether leucopoenia or other dose-related side-effects are less severe with a gradual escalation algorithm compared with starting at the weight-calculated dose has yet to be determined. Neither method prevents toxicity. In a study by Connell et al., the range of time from starting AZA to onset of leucopoenia was 2–11 years with a median of 9 months.32 Whereas in a study by Present et al. most of the cases of leucopoenia occurred within 1 month of starting MP.33 The dose escalating method chosen is arbitrary, but a common practice is to start at 50 mg everyday and increase the dose by 25 mg every 1–2 weeks and monitor for leucopoenia and other potential adverse events.

Use of metabolites: 6-TGN and 6-MMP. The metabolites 6-TGN and 6-MMP have been used to determine likelihood of therapeutic response. See Table 1 for metabolite levels and the associated response and/or toxicity. Non-responders to MP and AZA can be categorized into three groups based on levels of the metabolites 6-TGN and 6-MMP. (i) Low levels of both metabolites are likely a consequence of under dosing or non-compliance. (ii) Low 6-TGN and high 6-MMP may signify increased likelihood for hepatotoxicity and also suggest metabolic resistance to MP/AZA, shunting away from 6-TGN production.34 Early recognition of this pattern may lead to early replacement of AZA with another medication. (iii) A normal 6-TGN level likely represents refractoriness to AZA or MP.

Table 1.  Metabolite levels and possible clinical correlations*
6-TGN level6-MMP levelClinical response
  1. * Low 6-TGN is defined as <235 pmol/8 × 108 and high >450 pmol/8 × 108. High 6-MMP is defined as >5700 pmol/8 × 108.

  2. MMP, 6-methylmercaptopurine; MP, mercaptopurine.

LowLowSubtherapeutic dosing or non-compliance
LowHighMP resistant
NormalHighMP resistant or high risk for abnormal liver chemistries
NormalLowResponders or refractory
HighLowTrue refractory, responder or risk of leucopoenia
HighHighOver-dosed

The initial studies of metabolite levels and associated clinical response were studied in paediatric IBD patients predominately with CD with various disease severities, type of disease and disease distribution. The application of measuring metabolite levels in UC studies has not been as well evaluated. Discriminant levels of 235–250 pmol/8 × 108 have been considered predictive of response. Yet, several studies have shown subjects that were in remission receiving MP or AZA with 6-TGN levels lower than 235–250.35–39Table 2 provides the sensitivity, specificity and positive predictive value of using discriminant levels (>230, 235 and 250 pmol/8 × 108) to predict clinical remission based on data from published studies. The positive predictive value for remission of 6-TGN level >230–250 are poor to fair at best ranging from 24 to 83%. Overall, therapeutic drug monitoring with measuring 6-TGN levels in patients treated with AZA or MP may be most useful and can be considered in the following selected settings: patients suspected of non-compliance and possibly patients who are failing to respond to standard doses of drug. The latter has yet to be proven in a prospective controlled fashion. There is now an ongoing trial comparing the benefit of dosing based upon 6-TG levels vs. weight-based dosing.

Table 2.  Utility of 6-TGN level for determining remission of inflammatory bowel disease
Study and 6-TGN levelTotal number of subject (n)IBD populationSensitivity (%)Specificity (%)Positive predictive value (%)Negative predictive value (%)
  1. * pmol/8 × 108

  2. † Studies may have multiple measurements of 6-TGN.

Belaiche et al.36
 >250*28Adult CD26888336
 >23032787535
Cuffari et al.38
 >25082Adult CD, UC69868670
Dubinsky et al.39
 >23593Paediatric CD, UC65737060
Goldenberg et al.116
 >23574Adult CD, UC47822482
Gupta et al.117
 >235101Paediatric CD, UC54706467
Mardini and Arnold118
 >23044Adult CD, UC1006165100
Su et al.11929Adult CD, UC55734183
>230Subgroups    
 Luminal CD86806084
 Fistulizing CD33661783
 UC40713679
Cuffari earlier study12010Paediatric CD80838083

TPMT.  The TPMT enzyme activity and genotype are tests that are available on a commercial basis for testing. An increasing number of TPMT mutations leading to reduced enzyme are being identified. Normal levels of enzyme activity appear to be associated with more response than high levels of TPMT enzyme activity but both groups have a widely variable clinical response.40, 41 Low enzyme levels can lead to development of severe myelosuppression in the setting of MP/AZA therapy.42, 43

The relationship of leucopoenia and various TPMT genotypes in the setting of AZA or MP treatment has been the focus of several research studies. In a study by Colombel et al. of 75 patients whom developed leucopoenia while treated with AZA or MP, 10% of patients were homozygous for TPMT mutant alleles and 17% were heterozygous for TPMT mutant alleles.44 The median time to leucopoenia was significantly shorter in those with homozygous TMPT mutations, 1 month (range: 0–1.5) compared with 4 months (range: 1–18) in those with one mutant allele and 3 months (range: 0.5–87) in those with normal TPMT.44 It is not yet clear whether patients heterozygous for a TPMT mutation are more likely to develop leucopoenia compared to those with normal TPMT. In a study by Seddik et al. published in abstract form 75 subjects with CD that were starting AZA/MP treatment were assessed for TPMT mutations. Six (8%) of the subjects were heterozygous for a TPMT mutation and none was homozygous of a TPMT mutation. Seven (9%) of the subjects developed leucopoenia and only one subject was heterozygous for a TPMT mutation.45 In a case–control study by Curvers et al. published as an abstract subjects with TPMT variant alleles were compared to subjects with normal alleles for the risk of developing leucopoenia and the OR was 1.5 (95% CI: 0.7–3.2) for developing leucopoenia.46 In this study and others, the majority of myelosuppression cases occur with normal levels of TPMT enzyme activity.

The prevalence (one of 300) of low TPMT enzyme is high enough and the potential complications of myelosuppression severe enough for us to recommend obtaining a TPMT enzyme activity level prior to starting therapy. A few small studies have suggested that TPMT-deficient patients can safely use low doses of MP/AZA, but until more studies verify safety other immunomodulators should be considered.42, 47

In patients with intermediate TPMT enzyme activity, the risk of myelosuppression is not clearly increased when compared to those with normal TPMT enzyme activity. Until more studies are performed formal evidence-based recommendations to vary treatment (e.g. maximal dose used or rapidity of achieving maximal dose) based upon whether an individual has the wild type (full TPMT enzyme activity) or intermediate TPMT enzyme activity cannot be formally established. It is not yet clear whether TPMT genotype or phenotype can also be used to predict other adverse effects of AZA such as nausea, vomiting, hepatitis and pancreatitis because of conflicting data.48

Mean corpuscular volume.  Several studies have suggested that mean corpuscular volume (MCV) correlates with 6-TGN levels and perhaps may be used as surrogate marker for monitoring therapeutic dosing.36,49,50 A study by Thomas et al., showed that a change of MCV (mean change in MCV was 7.5 ± 6.3 fL) from baseline during treatment with AZA or MP was directly correlated with 6-TGN levels (r = 0.33, P < 0.001) and inversely correlated with leucocyte counts (r = 0.26, P = 0.001).50 A study by Belaiche et al. also showed a correlation of MCV with 6-TGN concentrations (r = 0.38, P = 0.048).36 Further studies are needed to determine the MCV level equivalent to a 6-TGN level.

Adverse events

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Several side-effects have been associated with MP/AZA use and include allergic reactions, pancreatitis, myelosuppression, nausea, infections, hepatoxicitiy and malignancy. Bone marrow suppression is related to levels of 6-TGN and may occur at any time during the duration of treatment.32 Therefore, monitoring of complete blood counts at regular intervals throughout the duration of therapy is suggested. It has been described that leucopoenia can occur in the setting of 6-TGN levels <230 pmol/8 × 108, but has also been associated with non-response to MP/AZA.39 Hepatoxicity is a rare complication and the pathophysiological mechanism of hepatic injury is unknown. Possibilities include drug-induced hepatitis, cholestasis, nodular regenerative hyperplasia and peliosis.33, 51 6-MMP levels >5700 pmol/8 × 108 is associated with hepatotoxicity, but patients may have high levels with normal liver chemistries and at low 6-MMP levels hepatotoxicity may occur.39 Routine measurement of 6-MMP for hepatotoxicity is not currently recommended, although the routine measurement of serum liver chemistries is recommended. A baseline measurement of serum liver chemistries should be obtained, then periodic measurements at least once every year thereafter. In patients developing nausea may be switched from AZA to MP or vice versa.52 Patients developing biochemical hepatitis or pancreatitis should have AZA or MP treatment discontinued. There have been several cases of lymphoma reported in AZA/MP users and may be partially related to infection with Epstein–Barr virus, but it is still unclear if there is a definitive increased risk.53–55

Several categories of drugs have been shown to possibly interact with MP and AZA metabolism and include medications that have 5-aminosalicylates (5-ASA) as the active moiety [sulfasalazine, mesalazine (mesalamine), olsalazine and balsalazide], allopurinol, aspirin and furosemide. In a study by Lowry et al. RBC 6-TGN levels were slightly higher but not statistically significant in subjects taking mesalazine, sulfasalazine or olsalazine concurrently compared with subjects not on these medications, 182 vs. 153 pmol/8 × 108 respectively (P = 0.10). The pathway of the drug interaction between MP/AZA and 5-ASA appears to be by inhibition of the TPMT enzyme which may lead to a higher risk for leucopoenia.56–59 Genetic variants of an intestinal epithelial enzyme arylamine-N-acetyl transferase, involved in 5-ASA metabolism, also appear to increase the risk for adverse events of MP therapy.60 Subjects on these medications should be more carefully monitored for myelosuppression.

Clinical pharmacology

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Ciclosporin is a lipophilic cyclic polypeptide that inhibits cytosolic enzyme calcineurin that leads to selective inhibition of interleukin (IL)-2 and interferon-γ production by T-helper cells, IL-3, IL-4, IL-5, tumour necrosis factor (TNF)-α and TNF-β.61 Bioavailability ranges from 10 to 89% and can be reduced by a fat-rich meal.62, 63 Ciclosporin is primarily metabolized by CYP3A4/5 in liver and the intestine and >90% is excreted in the bile.

Indication and dosing

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Ciclosporin is reserved for patients with severe UC that are refractory to steroid therapy. This is generally defined as persistently active colitis despite 7–10 days of high dose (equivalent to 40–60 mg of prednisone daily) intravenous steroids. The primary use is to induce remission and serve as a ‘bridge’ for MP/AZA therapy in UC patients with severe colitis.

This clinical use in UC was defined in a landmark article by Lichtiger et al. where hospitalized subjects with severe UC who failed intravenous steroids after 7 days were randomized to 4 mg/kg of intravenous ciclosporin or placebo. About 82% of subjects receiving ciclosporin responded compared with none that received placebo after 14 days of treatment (P < 0.001).64 In a later study, intravenous ciclosporin 4 mg/kg/day was compared with intravenous steroids 40 mg/day for the treatment of hospitalized subjects with UC for 8 days. About 64% of subjects receiving ciclosporin compared with 53% receiving intravenous steroids responded (P = N.S.).65 A more recent study has shown no significant difference in response of 2 mg/kg/day when compared with 4 mg/kg/day with fewer side-effects.66 There has not been a randomized placebo-controlled trial of ciclosporin for the maintenance of remission of UC.

There have been several controlled trials of intravenous ciclosporin for the treatment of CD with only one of three studies showing possible efficacy.67–69 Because of insufficient evidence of efficacy, ciclosporin is not recommended for the treatment of CD.

Monitoring

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

The initial studies of ciclosporin for treatment of IBD revealed a dose–response relationship between 200 and 400 ng/mL [monoclonal radioimmunoassay (RIA)] of whole blood ciclosporin. Non-responders were more likely if target blood concentrations were <200 ng/mL, whereas no additional benefit in efficacy has been observed with blood levels >400 ng/mL.64, 70

Baseline medical history, physical examination and laboratory studies are needed prior to initiation of therapy. Patients with a history of seizures, poor compliance to medical therapy, poorly controlled hypertension, and cancer are relative contraindications to starting ciclosporin.71 Pregnancy is also a relative contraindication to starting ciclosporin. In addition, a patient's medication list should be carefully reviewed for possible drug interactions. Active infection should be excluded prior to therapy and hypertension treated. Ciclosporin has a propensity to induce seizures in the setting of low serum cholesterol (≤120–140 mg/dL) or hypomagnesaemia.72 Baseline laboratory tests should include a serum creatinine, potassium, magnesium, cholesterol, complete blood count, liver chemistries, and a pregnancy test in women of child-bearing age. During the first hour of infusion it is advised to watch for signs of an allergic response such as wheezing, urticaria, hypotension every 15 min. Blood work except for serum cholesterol should be taken at minimum every second day. If blood work is abnormal including serum cholesterol, then blood work should be checked daily. Intravenous lipids have been used to boost borderline cholesterol levels. Corticosteroids and 5-ASA can be continued during therapy and MP/AZA discontinued.

A ciclosporin trough level should be obtained every 2 days with a goal blood level of 200–400 ng/mL assessed by high-performance liquid chromatography (HPLC), RIA or immunoassay. Ciclosporin level determined by HPLC is preferred because of immunoassays cross-reacting with ciclosporin metabolites.73–75 If the trough levels are above 500 ng/mL for 2 consecutive days, then ciclosporin dose should be reduced by at least 25%. Medications to be cognizant of that may increase serum levels due to a reduction of ciclosporin metabolism from inhibition of CYP3A4/5 include ketoconazole, erythromycin, grapefruit juice, calcium-channel blockers, bromocriptine, metoclopramide and danazol.76, 77 On the contrary, low levels of ciclosporin may be a result of medications that increase excretion and include medications such as rifampicin, phenobarbital, phenytoin, carbamazepine and St John's wort.78, 79 Other potential reasons for reducing the ciclosporin dose are if serum creatinine increases by 30% over baseline, serum liver enzymes double or diastolic blood pressure exceeds 90 mmHg (12 kPa) or systolic blood pressure exceeds 150 mmHg (20 kPa) despite antihypertensive treatment.

If patients do not respond to therapy after 10 days or their symptoms become worse during that time, then they should be referred to surgery. Otherwise, patients who respond to at least 7 days of intravenous ciclosporin should be switched to oral ciclosporin. Details about switching to oral ciclosporin are suggested in a recently published user's guide to ciclosporin use in severe UC.71 If ciclosporin is continued, then patients should also be started on trimethoprim/sulfamethoxazole 160/80 mg for prevention of pneumocystitis pneumonia. Thus far, there are no published randomized-controlled trial conducted evaluating an oral ciclosporin, for the treatment of active UC or maintenance of remission.

Adverse events

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Many of the potential adverse events were mentioned in the section on monitoring. Potential side-effects that have been reported in clinical trials for treatment of IBD of ciclosporin include hypertension, renal insufficiency, seizure, headache, nausea/vomiting, paresthesias, hypertrichosis, gingival hyperplasia and opportunistic infections. Adverse events that occurred in the intravenous ciclosporin trials for the treatment of UC are listed in Table 3. The mechanism of ciclosporin nephrotoxicity may be due to renal arteriole vasoconstriction. If hypertension were to develop calcium-channel blockers are preferred for the treatment of hypertension treatment because of their arteriole vasodilatation effects and protection from ciclosporin-induced nephrotoxicity. Pneumocystitis pneumonia has been reported during treatment with ciclosporin for other non-IBD indications and because of this potential risk trimethoprim/sulfamethoxazole prophylaxis is recommended in those patients receiving ciclosporin >7 days.

Table 3.  Adverse events in trials of intravenous ciclosporin for ulcerative colitis*
 Lichtiger and Present121Lichtiger et al.64Hermida-Rodriguez et al.122†*D'Haens et al.65Van Assche et al.66
  1. † No control group.

  2. ‡ Ten of 11 subjects with mean blood levels provided, based on radioimmunoassay technique.

  3. § Enzyme multiplied immuno test.

  4. ¶ Monoclonal antibody-based fluorescence polarization immunoassay technique.

  5. NR, not reported.

  6. * Also included Crohn's disease patients.

Duration of study (days)10≤147–1088
Ciclosporin dose (mg/kg)44442 vs. 4
Ciclosporin mean blood levels (ng/mL)NR482‡250§376¶237/332¶
Response ciclosporin/control (%)7382/07064/5386/84
Paresthesias ciclosporin/control (%)40¶36/000/76/8
Hypertension ciclosporin/control (%)1336/1107/09/24
Nausea/vomiting ciclosporin/control (%)09/1147/0NR
Nephrotoxicity ciclosporin/control (%)70/090/017/18
Hepatoxicity ciclosporin/control (%)00/00NRNR

Clinical pharmacology

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Methotrexate is a folic acid antagonist that leads to the inhibition of purine synthesis, DNA and RNA formation, and eventually inhibition of the S-phase of the cell cycle. Intracellular, methotrexate is converted to the active metabolite methotrexate polyglutamate by the enzyme folate polyglutamase synthase. Dihydrofolate reductase (DHFR), an enzyme involved in converting folate to tetrahydrofolate, is inhibited by binding to both methotrexate and methotrexate polyglutmate.80–82 Increased DHFR transcription is associated with decreased responsiveness to methotrexate and recently SNPT829C located in the untranslated region of the DHFR gene has been shown to be associated with increased levels of DHFR mRNA.83

Methotrexate polyglutamate is also capable of inhibiting other enzymes in the pathway of folate metabolism leading to purine nucleotide synthesis. The actual cell targets of methotrexate involved in the suppression of inflammation in chronic inflammatory conditions are not known. Potential target cells include cells within the lamina propria of the intestine, intestinal intraepithelial lymphocytes, leucocytes, monocytes-macrophages and intestinal epithelial cells. In vitro and in vivo studies have shown increased levels of extracellular adenosine associated with methotrexate therapy, however, in a small clinical study of 10 IBD patients plasma adenosine and rectal tissue adenosine levels were not found to be elevated after receiving methotrexate 15 or 25 mg subcutaneously once every week.84 Neutrophils, lymphocytes and macrophages all have receptors for adenosine that appears to suppress cytokine release from these cell line.85 Adenosine also appears to inhibit the production of reactive oxygen metabolites, adhesion to and injury of endothelial cells, synthesis and release of leukotriene B4, and production of TNF-α in neutrophils.82 In macrophages/monocytes TNF-α, IL-6 and IL-8 production are inhibited and there is increased promotion the IL-1 receptor antagonist and secretion of IL-10.82

Oral methotrexate is well absorbed, but this appears to be in dose-dependent fashion.86 Lower doses of methotrexate are better absorbed than higher doses (>25 mg/week).86, 87 This dose effect may be related to metabolism by intestinal bacteria. Intramuscular (I.M.) and subcutaneous (S.Q.) formulations of methotrexate have near complete bioavailability and have been shown to have high concentrations in intestinal mucosa.88 It has been suggested that methotrexate is primarily delivered to the intestinal mucosa by the blood stream rather than direct intestinal absorption into sites of inflammation because of higher concentrations of methotrexate in rectal mucosa given in the I.M. or S.Q. form compared with oral methotrexate. Methotrexate is primarily excreted by the kidneys.

Indication and dosing

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Methotrexate was initially used in rheumatoid and psoriatic arthritis, but has been found to be useful for many chronic inflammatory conditions. Methotrexate has been shown to be beneficial in the treatment of steroid refractory CD.89

There have been several uncontrolled studies and randomized-control studies suggesting a benefit for the induction of remission, steroid-sparing effects, and maintenance of remission for CD.90–96 There have been a small number of uncontrolled studies and one randomized-control study evaluated the efficacy of methotrexate for UC.89, 91, 95, 97, 98 In the initial study, five of seven patients were induced into remission showing possible benefit was by Kozarek et al.89 In a recent study by Paoluzi et al., 10 patients whom could not tolerate or were resistant to AZA were given methotrexate 12.5 mg/week I.M. for active UC. Six subjects were induced into remission and four subjects had significant improvement based on clinical, endoscopic and histological examinations after 6 months of therapy.98 In the one randomized-controlled study by Oren et al., methotrexate 12.5 mg/week per oral (PO) was compared with placebo after 9 months for inducing active UC into remission. About 47% of methotrexate subjects after a median of 4.1 ± 1.9 months went into remission compared with 49% of placebo subjects after 3.4 ± 1.7 months.91 Although this study did not show a benefit perhaps I.M. or SQ and higher doses may be effective. The role of methotrexate in UC still remains unclear.

For the treatment of active CD, methotrexate doses of 15–25 mg S.Q./I.M. for 12–16 weeks may be considered. Based on clinical trial results oral methotrexate has been shown to be modestly superior to placebo at best at doses from 12.5 to 22.5 mg.92 Oral bioavailability of methotrexate has been reported approximately 73% (95% CI: 0.62–0.86) compared with S.Q. administration with minimal change of bioavailability when given with folate.99 If patients are switched to an oral formulation of methotrexate, then the equivalent S.Q. dose needs to be determined. Once a patient is in remission, maintenance treatment is recommended with either continuation of methotrexate at 15 mg S.Q./I.M. or starting AZA, MP or 5-ASA.

Monitoring

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

There are no specific metabolites available to monitor therapy for efficacy or side-effects. Because of the potential myelosuppression and hepatotoxicity total blood cell counts and liver enzymes should be monitored regularly every 1–3 months. In a study by Feagan et al., seven of 94 patients treated with methotrexate in a 16-week trial for active CD had transaminases greater than twice the upper limits of normal and persisted after 1 week despite cessation of methotrexate.90 In this study, no patients were withdrawn because of leucopoenia. In a 40-week maintenance study of methotrexate in CD in remission there were no patients withdrawn due to leucopoenia or abnormal liver enzymes.96 A single point in time liver enzyme elevation has been shown to be a poor predictor of severity of liver, whereas persistent enzyme elevation on serial measurement appears to correlate with liver histology.100 The Psoriasis Task Force suggest a liver biopsy pre-treatment, if a patient will be on methotrexate long-term and after a patient has received a cumulative methotrexate dose of 1.5 g.101 Indications for liver biopsy from the American College of Rheumatology are (i) pre-treatment biopsy for a history of excessive alcohol consumption, persistently abnormal aspartate aminotransferase (AST) or chronic hepatitis B or C infection, (ii) during treatment biopsy for persistently abnormal liver function tests defined as elevations of AST in five of nine determinations within a given 12-month interval or a decrease in serum albumin below the normal range. In a recent case series of 20 IBD patients taking methotrexate (mean accumulated dose of 2633 mg) only one had liver fibrosis by liver biopsy.102 This suggests that IBD patients may be at lower risk for liver fibrosis than psoriasis or rheumatoid patients. If liver enzymes are abnormal, we recommend rechecking liver enzymes after a short interval, i.e. 1-month interval. If the liver enzymes remain elevated, then a liver biopsy should be considered as well as a work-up for other possible aetiologies. Whether to obtain a liver biopsy after a methotrexate cumulative dose of 1.5 g is unclear taking into consideration the possible lower likelihood for hepatic fibrosis in IBD patients when compared with psoriasis and rheumatoid arthritis. Further studies are needed in the IBD population to determine the need for liver biopsy.

Adverse events

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Methotrexate has been used for diseases such as psoriasis and rheumatoid arthritis long before its use in IBD, so its side-effect profile has been well-documented. Major adverse events reported include hepatotoxicity, myelosuppression, pneumonitis in 3–12%, infertility and foetal malformation, and enteritis/colitis. Minor adverse events reported include nausea, vomiting, diarrhoea, stomatitis, alopecia, rash and neurological changes.87 Hepatoxicity is a well-known side-effect of treatment. Although studied in a non-IBD population, the changes in liver histology include macrovescicular steatosis, nuclear variability, chronic inflammatory infiltrates in the portal tracts, hepatocyte necrosis, fibrosis and cirrhosis. Hepatic fibrosis and cirrhosis are the most concerning long-term potential toxicities and tend to occur with accumulated methotrexate use of >1.5 g. Myelosuppression is known potential side-effect of methotrexate, but it is uncommon if the duration of therapy is <1 year.103 Infections reported in methotrexate users include pneumocystitis carinii pneumonia, herpes zoster, cytomegalovirus, Epstein–Barr virus and Listeria monocytogenes.104–107 There have been several case reports of lymphoma in rheumatoid arthritis patients and other connective tissue disorders treated with methotrexate with resolution of lymphoma once methotrexate is stopped.108–110 Many of the lymphomas reported have been associated with Epstein–Barr virus. Although, there has yet been a controlled study verifying an increased risk for lymphoma in subjects using methotrexate.

In the four randomized trials of methotrexate for the treatment of CD for durations ranging from a minimum of 4– 12 months and doses ranging from a minimum of 12.5 mg PO/week to 25 mg i.m./week, the most common side-effects were nausea and elevation of liver enzymes.90, 92, 93, 96 In the rheumatoid arthritis population folate and folinic acid supplementation to methotrexate therapy has been found effective in reducing side-effects in a systematic review, meta-analysis and a randomized-controlled trial.111–113 Folate and folinic acid have not been found to be different in their effectiveness for reducing side-effects from methotrexate therapy, but folinic acid is more expensive than folate. To avoid potential toxicities folate supplementation is recommended, either 1 mg per mg of methotrexate divided into daily doses or 0.25–0.50 mg per mg of methotrexate given 4–24 h after administration of weekly methotrexate.114, 115

Conclusion

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References

Drug monitoring for effectiveness and side-effects of immunomodulators is paramount. Table 4 provides a guide to pre-treatment and during treatment drug monitoring. With recent biomedical technology advances our understanding of the metabolic consequence of this class of drugs in vivo has grown. Yet we are still at the infancy stage of understanding and fine tuning these advances. As a consequence, there is still a dearth of information on evidence for monitoring for effectiveness and side-effects of these medications within the IBD population. The algorithms and suggestions provided are partly subjective but encompass our best-educated advice due to lack of literature in this area. Studies are still needed to: (i) clarify the role of 6-TGN for measuring efficacy of AZA and MP, (ii) cost-effectiveness of TPMT testing prior to starting AZA and MP therapy, (iii) determine the best starting dose in individuals with intermediate TMPT activity, (iv) determine the optimal frequency of surveillance blood testing in out-patients (such as complete blood count and liver function test) in individuals treated with immunomodulators and (v) determine the role of liver biopsy in the IBD population after receiving a cumulative dose of >1.5 g of methotrexate. As the indications for use of immunomodulators broadens for the treatment of IBD, monitoring for efficacy and side-effects will be even more critical.

Table 4.  Laboratory monitoring of immunomodulators*
ImmunomodulatorPre-treatment assessmentTreatment assessment
  1. * TPMT, thiopurine methyltransferase; 6-MMP, 6-methylmercaptopurine; CBC, complete blood count; LFT, liver function test.

Azathioprine/ MercaptopurineTPMTCBC
CBCLFT
LFTMetabolites (6-TGN, 6-MMP)
CiclosporinCBCCBC
LFTLFT
Serum electrolytes (potassium, magnesium)Serum electrolytes (potassium, magnesium)
Serum creatinineSerum creatinine
Serum cholesterolSerum cholesterol
 Ciclosporin level
MethotrexateCBCCBC
LFTLFT

References

  1. Top of page
  2. Summary
  3. Introduction
  4. Methods
  5. Mercaptopurine and azathioprine
  6. Clinical pharmacology
  7. Indication and dosing
  8. Monitoring
  9. Adverse events
  10. Ciclosporin
  11. Clinical pharmacology
  12. Indication and dosing
  13. Monitoring
  14. Adverse events
  15. Methotrexate
  16. Clinical pharmacology
  17. Indication and dosing
  18. Monitoring
  19. Adverse events
  20. Conclusion
  21. Acknowledgement
  22. References
  • 1
    Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 113345.
  • 2
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 32939.
  • 3
    Alves S, Prata MJ, Ferreira F, Amorim A. Screening of thiopurine S-methyltransferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat 2000; 15: 24653.
  • 4
    Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26: 2206.
  • 5
    Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 27990.
  • 6
    Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 3716.
  • 7
    Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 13646.
  • 8
    Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 6073.
  • 9
    Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 60814.
  • 10
    Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 6015.
  • 11
    Weinshilboum RMSS. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 65162.
  • 12
    Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schmiegelow K. Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 17: 658.
  • 13
    Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 32333.
  • 14
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 13242.
  • 15
    Willoughby JMBJ, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 9447.
  • 16
    Klein MBH, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66: 91622.
  • 17
    Present DHKB, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomized double-blind study. N Engl J Med 1980; 302: 9817.
  • 18
    Ewe KPA, Singe CC, Stufler M, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 36772.
  • 19
    Candy SWJ, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 6748.
  • 20
    Rosenberg JLLB, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20: 7216.
  • 21
    Sandborn WSL, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 00: CD000545.
  • 22
    Pearson DCMG, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 00: CD000067.
  • 23
    Caprilli RCR, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalizine in idiopathic proctocolitis. Am J Dig Dis 1975; 20: 11520.
  • 24
    Korelitz BHS, Rutgeerts P, Present D, Peppercorn M. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multi-center trial. Gastroenterology 1998; 114: A1011.
  • 25
    Cuillerier E, Lemann M, Bouhnik Y, Allez M, Rambaud JC, Modigliani R. Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol 2001; 13: 12916.
  • 26
    Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993; 88: 1198205.
  • 27
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 7239.
  • 28
    Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127: 73040.
  • 29
    Markowitz JGK, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895902.
  • 30
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 2159.
  • 31
    Treton XBY, Mary JY, Colombel JF, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission under treatment is associated with a high risk of relapse. Gastroenterology 2004; 126: A113.
  • 32
    Connell WRKM, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 10815.
  • 33
    Present DHMS, Krumholz MP, Wolke A, Korelitz BL. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989; 111: 64149.
  • 34
    Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 90415.
  • 35
    Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 4016.
  • 36
    Belaiche JDJ, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol 2001; 36: 716.
  • 37
    Sandborn WJTW, Wolf DC, Targan SR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroids-treated Crohn's disease. Gastroenterology 1999; 117: 52735.
  • 38
    Cuffari C, Hunt S, Bayless T. Utilization of erthyrocyte 6-thioguinine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 39
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 40
    Cuffari CDT, Turnbaugh L, Thompson R, Bayless TM. Thiopurine methyltransferase (TPMT) activity influences clinical response to maintenance azathioprine in patients with IBD. Gastroenterology 2002; 122: A221.
  • 41
    Pettersson BAS, Albertioni F, Soderhall S, Peterson C. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 2002; 24: 35158.
  • 42
    Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293301.
  • 43
    Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119: 9859.
  • 44
    Colombel JFFN, Debuysere H, Marteau P, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 102530.
  • 45
    Seddik MTF, Ferrari N, Cortot A, Libersa C, Broly F, Colombel J. Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease (abstract). Gastroenterology 2003; 125: s1311.
  • 46
    Curvers WDL, Stokkers P, Vogels E, et al. No predictive value of TPMT genotyping for leucopenia of hepatoxicity during azathioprine therapy in inflammatory bowel disease (abstract). Gastroenterology 2003; 124: A377.
  • 47
    Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 1402.
  • 48
    Ho G-T, Lees C, Satsangi J. Pharmacogenetics and inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 14858.
  • 49
    Decaux GPF, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 25662.
  • 50
    Thomas CW Jr, Lowry PW, Franklin CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 23745.
  • 51
    Bouhnik YLM, Mary JY, Scemama G, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 2159.
  • 52
    Cheng B, Lichtenstein GR. Are individuals with Crohn's disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine? Gastroenterology 2000; 118: A1336.
  • 53
    Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 727.
  • 54
    Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 10807.
  • 55
    Aithal GP, Mansfield JC. Review article: The risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001; 15: 11018.
  • 56
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 4569.
  • 57
    Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 46475.
  • 58
    Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 65664.
  • 59
    Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev 2000; 19: 293312.
  • 60
    Projuansky R, Maxwell M, Johnson J, et al. Molecular genotyping predicts complications of 6-mercaptopurine therapy in childhood IBD. Gastroenterology 1999; 116: A800.
  • 61
    Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 72351.
  • 62
    Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 47295.
  • 63
    Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995; 50: 92441.
  • 64
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 18415.
  • 65
    D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 13239.
  • 66
    Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 102531.
  • 67
    Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 84550.
  • 68
    Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 184651.
  • 69
    Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995; 109: 77482.
  • 70
    Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39: 37480.
  • 71
    Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997; 92: 14248.
  • 72
    de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 8616.
  • 73
    Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 1999; 45: 37181.
  • 74
    Steimer W. Evaluation of the AxSYM CyA assay compared with HPLC, TDx monoclonal and EMIT with both pretreatments. Transplant Proc 1998; 30: 40457.
  • 75
    Schutz E, Svinarov D, Shipkova M, et al. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem 1998; 44: 215864.
  • 76
    Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 10321.
  • 77
    Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84112.
  • 78
    Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 159.
  • 79
    Greeson JM, Sanford B, Monti DA. St John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001; 153: 40214.
  • 80
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 42333.
  • 81
    Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992; 16: 41123.
  • 82
    Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23: 73955.
  • 83
    Goto Y, Yue L, Yokoi A, et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 2001; 7: 19526.
  • 84
    Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis 1999; 5: 16773.
  • 85
    Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 415968.
  • 86
    Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11: 56973.
  • 87
    Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996; 71: 6980.
  • 88
    Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978; 3: 113.
  • 89
    Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 3536.
  • 90
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 2927.
  • 91
    Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 141621.
  • 92
    Oren RMM, Odes S, Becker S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 22039.
  • 93
    Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 17249.
  • 94
    Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 17304.
  • 95
    Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38: 18516.
  • 96
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 162732.
  • 97
    Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 6937.
  • 98
    Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 17519.
  • 99
    Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 5763.
  • 100
    West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997; 23: 883915.
  • 101
    Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 14556.
  • 102
    Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 31506.
    Direct Link:
  • 103
    Cunliffe RN, Scott BB. Review article: Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 64762.
  • 104
    Jarrett P, Ha T, Oliver F. Necrotizing fasciitis complicating disseminated cutaneous herpes zoster. Clin Exp Dermatol 1998; 23: 878.
  • 105
    LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150: 25860.
  • 106
    Jansen TL, van Heereveld HA, Laan RF, Barrera P, van de Putte LB. Septic arthritis with Listeria monocytogenes during low-dose methotrexate. J Intern Med 1998; 244: 8790.
  • 107
    Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren's syndrome: case series. J Rheumatol 2001; 28: 4753.
  • 108
    Bologna C, Picot MC, Jorgensen C, Viu P, Verdier R, Sany J. Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 1997; 56: 97102.
  • 109
    Baird RD, van Zyl-Smit RN, Dilke T, Scott SE, Rassam SM. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 2002; 118: 5678.
  • 110
    Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus? J Rheumatol 2001; 28: 25735.
  • 111
    Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; 00: CD000951.
  • 112
    Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. J Rheumatol 1998; 25: 3643.
  • 113
    van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 151524.
  • 114
    Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 115861.
  • 115
    Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36: 795803.
  • 116
    Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 17448.
    Direct Link:
  • 117
    Gupta P, Gokhale R, Kirschner BS. 6-Mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 4504.
  • 118
    Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003; 36: 3905.
  • 119
    Su CWS, Deren J, Weinberg A, Lichtenstein GR. Measurement of 6-TG Levels with IBD: are all groups identical? Gastroenterology 2002; 122: A78.
  • 120
    Cuffari C. MP, azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology 1999; 116: A694.
  • 121
    Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 169.
  • 122
    Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, Pajares Garcia JM, Mate-Jimenez J. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology 1999; 46: 22658.